scholarly journals CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH TERMINAL RENAL INSUFFICIENCY

2014 ◽  
Vol 5 (2) ◽  
pp. 30-34
Author(s):  
A N Fedoseev ◽  
A S Vaulina ◽  
V V Smirnov ◽  
K V Ovsyannikov
Keyword(s):  
Renal Insufficiency ◽  
Reactive Hyperemia ◽  
Chronic Kidney Disease Stage ◽  
Simultaneous Detection ◽  
Vascular Wall ◽  
Disease Stage ◽  
End Stage Renal Failure ◽  
Endothelin 1 ◽  
Vasodilating Activity ◽  
End Stage

The problem of development of endothelial disfunction in patients with end-stage renal failure and possibilities of its correction in extracorporal and medical methods is discussed.In research took part 60 patients with chronic kidney disease stage V by K/DOQI, which was evaluated vasomotor endothelial function in samples with reactive hyperemia and nitroglycerin, with simultaneous detection of the concentration of endothelin-1. The study confirmed the expressed changes of indicators vasodilating activity of the vascular wall and raising of endothelin-1 level in patients of this group. Effective method of correction of endothelial disfunction in patients with terminal renal insufficiency was early initiation of haemodyalisis therapy in combination with ACE inhibitors pharmacotherapy.

scholarly journals CHANGES OF NONESSENTIAL TRACE ELEMENTS LEVELS IN WHOLE BLOOD OF END STAGE RENAL DISEASE ADULT PATIENTS

2017 ◽  
pp. 114-125
Author(s):  
O. O. Makarov ◽  
E. O. Pisarev ◽  
B. S. Sheiman ◽  
M. V. Kulizkiy ◽  
D. V. Peretyatko ◽  
...  
Keyword(s):  
Trace Elements ◽  
Whole Blood ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Blood Levels ◽  
Healthy Donors ◽  
Plasma Mass Spectrometry ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Aims: Accumulation of trace elements occurs in conditions of decreased or termination of kidneys functions. In some conditions increased trace elements can obtain toxic features. On other hand, researches are showing that concentration of some trace elements could be decreased in ERSD patients, too. The most important factor affecting trace element concentration in ERSD patient is the degree of renal failure and using of replacement therapy. Materials and methods: We determined the concentration of microelements (beryllium, boron, aluminum, vanadium, chromium, nickel, arsenic, rubidium, strontium, cadmium, cesium, barium, thallium and lead) in whole blood of 41 ESRD patients with chronic kidney disease stage VD, who were treated with hemodialysis / hemodiafiltration and in 61 conditionally healthy donors. Determination of whole bloods trace elements content was conducted using inductive coupled plasma mass- spectrometry (ICPMS).  Results: It is determinate that levels of beryllium, boron, aluminum, vanadium, chromium, strontium, cadmium, barium, thallium and lead is reliable increased in ESRD patients. Decreased levels are observed for nickel, arsenic, cesium and rubidium. Conclusions: ESRD is accompanied with substantial and multidirectional changes of trace elements blood levels. During researches has shown that in ESRD patients processes of trace elements accumulation are prevailing over elimination ones.

Effect of a Hemodialysis Session on Plasma Levels of Endothelin-1 in Hypertensive and Normotensive Subjects with End-Stage Renal Failure

Nephron ◽  
1999 ◽  
Vol 81 (1) ◽  
pp. 31-36 ◽  
Author(s):  
Andrzej Surdacki ◽  
Władysław Sułowicz ◽  
Ewa Wieczorek-Surdacka ◽  
ZbigniewS. Herman
Keyword(s):  
Renal Failure ◽  
Plasma Levels ◽  
End Stage Renal Failure ◽  
Endothelin 1 ◽  
Hemodialysis Session ◽  
Normotensive Subjects ◽  
End Stage

scholarly journals Comparing Nephrolithiasis with Nephrocalcinosis in Children; A Study From Two Tertiary Centers in Saudi Arabia

2021 ◽  
Author(s):  
Khalid Alhasan ◽  
Mohamed Shalaby ◽  
Amr Albanna ◽  
Mohamad-Hani Temsah ◽  
Zainab Alhaik ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Kidney Disease ◽  
Clinical Outcomes ◽  
Chronic Kidney Disease Stage ◽  
Failure To Thrive ◽  
Bartter Syndrome ◽  
Disease Stage ◽  
Tubular Lumen ◽  
Renal Tubular ◽  
End Stage

Abstract Background: Nephrolithiasis and nephrocalcinosis is uncommon in children; however, its incidence is increasing. Patients and Methods: A multicenter retrospective study of the clinical presentation, etiology, and outcome of childhood nephrolithiasis and compare it with nephrocalcinosis.Results: The study included 144 children; 93 with nephrolithiasis (formation of stones within renal pelvis or tubular lumen) and 51 with nephrocalcinosis. (deposition of calcium in the renal parenchyma) Mean age at presentation were 72 months and 54 months for nephrolithiasis and nephrocalcinosis, respectively. In 64.8% of the nephrolithiasis and 76% of nephrocalcinosis cases, a history of consanguinity was found. Congenital anomalies of the kidneys and urinary tract were present in 28% and 9.8% of those with nephrolithiasis and nephrocalcinosis, respectively. The most common symptoms of nephrolithiasis were flank pain (29%), hematuria (15%), and dysuria (11%). Urinary tract infection was the primary presentation in the nephrocalcinosis group (18%) followed by failure to thrive (16%), polyuria (12%), and dehydration (12%).The majority of nephrolithiasis cases were caused by metabolic disorders. In contrast, the most common underlying disorders for nephrocalcinosis were familial hypomagnesemia hypercalciuria nephrocalcinosis (35%), distal renal tubular acidosis (23%), and Bartter syndrome (6%).Clinical outcomes were significantly better in children with nephrolithiasis than those with nephrocalcinosis who had radiological evidence of worsening/persistent calcinosis and progressed more frequently to chronic kidney disease (stage II-IV) and end stage kidney disease.Conclusion: The etiology of nephrolithiasis can be identified in many children. Nephrocalcinosis is associated with worse clinical outcomes related to kidney function and disease resolution as compared to nephrolithiasis.

scholarly journals Baclofen Toxicity in a Chronic Kidney Disease Stage 5D Patient

2018 ◽  
Vol 1 (1) ◽  
pp. 53-55
Author(s):  
Sarju Raj Singh ◽  
Manisha Dhakal ◽  
Santosh Thapa ◽  
Sudha Khakurel
Keyword(s):  
Chronic Kidney Disease Stage ◽  
Clinical Manifestations ◽  
Disease Stage ◽  
Maintenance Hemodialysis ◽  
History Of ◽  
Muscular Spasm ◽  
Stage Renal Disease ◽  
End Stage ◽  
Intensive Hemodialysis ◽  
Infectious Etiology

The toxicity of Baclofen is extremely unusual. However, its predominant renal clearance makes its vulnerable in patients with impaired renal function. Clinical manifestations may begin as early as 2-3 days after starting the drug, even with a smaller dosage.A 73-year-old man with end-stage renal disease on maintenance hemodialysis was admitted to our emergency department with progressive confusion, hallucination and a generalized decrease in muscular tone. There was no significant metabolic or infectious etiology that could have clarified his condition. A thorough laboratory and imaging workup was negative too. A detailed history of his medication revealed that he had recently been prescribed baclofen for neck muscular spasm (10mg twice daily). He was then diagnosed with baclofen toxicity and was treated with intensive hemodialysis. During his admission, few sessions of hemodialysis on consecutive days, eventually produced expected clinical improvement and a complete return to his previous baseline mental status.Nepalese Medical Journal, vol.1, No. 1, 2018, page: 54-56

scholarly journals Subclavian vein angioplasty during arteriovenous fistula surgery: case report and literature review

2012 ◽  
Vol 11 (2) ◽  
pp. 154-157
Author(s):  
Marcus Vinícius Martins Cury ◽  
Marcelo Fernando Matielo ◽  
Ana Carolina Calixtro ◽  
Giuliano de Almeida Sandri ◽  
Marcos Roberto Godoy ◽  
...  
Keyword(s):  
Case Report ◽  
Arteriovenous Fistula ◽  
Subclavian Vein ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Stage Renal Disease ◽  
End Stage ◽  
Vein Stenosis ◽  
Subclavian Stenosis

Patients with chronic kidney disease stage 5 are generally treated by hemodialysis, preferentially performed via an arteriovenous fistula (AVF). We report the case of a 58-year-old male patient with diabetes mellitus, hypertension and end-stage renal disease in whom hemodialysis was conducted via a long-term catheter. His medical record described numerous central venous cannulations and several AVF creations. The patient developed subclinical subclavian stenosis that required creation of a new vascular access route. The purpose of this case report is to describe treatment of subclavian vein stenosis during AVF creation.

BASAL AND TRH-STIMULATED THYROID AND PITUITARY HORMONES IN VARIOUS DEGREES OF RENAL INSUFFICIENCY

1979 ◽  
Vol 90 (1) ◽  
pp. 23-32 ◽  
Author(s):  
M. Weissel ◽  
H. K. Stummvoll ◽  
H. Kolbe ◽  
R. Höfer
Keyword(s):  
Renal Failure ◽  
Renal Insufficiency ◽  
Pituitary Hormones ◽  
Mean Value ◽  
Advanced Stage ◽  
Thyrotrophin Releasing Hormone ◽  
End Stage Renal Failure ◽  
Failure Group ◽  
Group 2 ◽  
End Stage

ABSTRACT Abnormalities of thyroid and pituitary function are well recognized in patients with end-stage renal failure. We have investigated the influence of varying degrees of renal insufficiency on serum thyroid (total thyroxine, TT4; total 3,5,3′-triiodothyronine, TT3, and 3′,5′,3′-triiodothyronine, reverse T3) and pituitary (thyrotrophin, TSH; growth hormone, GH; prolactin, PRL) hormone levels before and after 200 μg thyrotrophin releasing hormone (TRH) iv administration. Patients with mild renal insufficiency (= group 1, plasma creatinine (Cr) > 1.3 mg% but < 3.0 mg%) had normal basal and TRH-stimulated hormone concentrations. In patients at a more advanced stage of the disease (= group 2; Cr > 3.0 mg % but < 7.0 mg %) basal hormone concentrations were also normal. In contrast to the normal group, where no GH reaction to TRH could be detected, GH serum concentrations increased in these patients after TRH. The TT3 and PRL response to TRH remained normal. The TSH reaction to TRH was blunted in four, normal in two and exaggerated in one patient. Patients with end-stage renal failure (= group 3; Cr > 7.0 mg%) had significantly decreased basal TT3 concentrations but a normal TT3 response to TRH. Basal TT4, TT3 and TSH concentrations were normal. The TSH reaction was blunted in four and normal in three patients. The mean basal GH was elevated, albeit not significantly different from the control mean value. The GH increase after TRH was even more pronounced than in group 2. Basal PRL concentrations were significantly increased, but maximal differences between basal and TRH-stimulated concentrations were not significantly different from control. Our data suggest that changes in the pituitary and hypothalamic control of GH are an early consequence of renal insufficiency. Alterations in thyroid function occur simultaneously on the pituitary – hypothalamic and peripheral level at a more advanced stage of the disease. PRL basal levels increase with decreasing renal function. In contrast to other studies we could not observe any significant influence of uraemia on the TRH-stimulated PRL reserve of the pituitary.

scholarly journals Calcium, Phosphorus and PTH in Patients with End Stage of Chronic Kidney Disease, Undergoing Hemodialysis

2020 ◽  
Vol 3 (2) ◽  
pp. 21
Author(s):  
Serfa Faja ◽  
Amir Shoshi
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Treatment Options ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Calcium Phosphorus ◽  
End Stage

Renal hyperparathyroidism (rHPT) is a common complication of chronic kidney disease characterized by elevated parathyroid hormone levels secondary to derangements in the homeostasis of calcium, phosphate, and vitamin D. Patients with rHPT experience increased rates of cardiovascular problems and bone disease. The Kidney Disease: Improving Global Outcomes guidelines recommend that screening and management of rHPT be initiated for all patients with chronic kidney disease stage 3 (estimated glomerular filtration rate, - 60 mL/min/1.73 m2). Since the 1990s, improving medical management with vitamin D analogs, phosphate binders, and calcimimetic drugs has expanded the treatment options for patients with rHPT, but some patients still require a parathyroidectomy to mitigate the sequelae of this challenging disease.

Sign in / Sign up

Export Citation Format

Share Document